Logo

Nyxoah Entered into a Distribution Agreement with Acurable for AcuPebble SA100 Home Sleep Test to Treat Obstructive Sleep Apnea in Germany

Share this
Nyxoah Entered into a Distribution Agreement with Acurable for AcuPebble SA100 Home Sleep Test to Treat Obstructive Sleep Apnea in Germany

Nyxoah Entered into a Distribution Agreement with Acurable for AcuPebble SA100 Home Sleep Test to Treat Obstructive Sleep Apnea in Germany

Shots:

  • The companies collaborated to provide AcuPebble SA100 home sleep test for OSA patients with expected availability in Q4'22 in Germany. The test will use acoustic signals for OSA while recorded signals are uploaded to a secure cloud platform & patented algorithms extract OSA parameters for the automatic diagnostic report shortly using a smartphone application
  • A randomized trial published in the BMJ Open showed that the test outperformed the gold-standard polygraphy test in terms of high levels of sensitivity & specificity for AHI & ODI
  • The test received a CE mark & the US FDA clearance and is designed for easier diagnosis & routinely monitor the patient's condition

Ref: GlobeNewswire | Image: Nyxoah

 

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions